Back to top

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: Results from the United Kingdom Clinical Practice Research Datalink

Citation

Wilding J, Godec T, Khunti K, Pocock S, Fox R, Smeeth L, et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: Results from the United Kingdom Clinical Practice Research Datalink. BMC Medicine. 2018;16(1)

Abstract

Intensification of metformin monotherapy with additional glucose-lowering drugs is often required in patients with type 2 diabetes (T2D). This study evaluated changes in HbA1c and weight, as well as treatment persistence, associated with different second-line therapies used in UK clinical practice.

Access publication here